GT-220F
/ Geode Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 10, 2025
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
(clinicaltrials.gov)
- P1 | N=42 | Not yet recruiting | Sponsor: Geode Therapeutics Inc.
New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1